These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38977466)

  • 1. Immunohistochemical analysis of tumor budding in stage II colon cancer: exploring zero budding as a prognostic marker.
    Pihlmann Kristensen M; Korsgaard U; Timm S; Frøstrup Hansen T; Zlobec I; Kjær-Frifeldt S; Hager H
    Virchows Arch; 2024 Oct; 485(4):691-701. PubMed ID: 38977466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer.
    Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Shimazaki H; Hase K; Ueno H
    Histopathology; 2019 Jun; 74(7):1005-1013. PubMed ID: 30698857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program.
    Pihlmann Kristensen M; Korsgaard U; Timm S; Hansen TF; Zlobec I; Hager H; Kjær-Frifeldt S
    Hum Pathol; 2024 Apr; 146():15-22. PubMed ID: 38428823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
    Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
    Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria.
    Landau MA; Zhu B; Akwuole FN; Pai RK
    Int J Surg Pathol; 2019 Apr; 27(2):147-158. PubMed ID: 29992847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
    Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
    Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer.
    Du C; Xue W; Dou F; Peng Y; Yao Y; Zhao J; Gu J
    Int J Biol Markers; 2017 Jul; 32(3):e267-e273. PubMed ID: 28478638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
    Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
    J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas?
    Secinti IE; Ozgur T; Gursoy D; Dede I
    APMIS; 2022 Sep; 130(9):560-567. PubMed ID: 35816469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Budding as a Prognostic Marker in Primary Colon Cancer - A Single Center Experience.
    Dukoska DB; Zdravkovski P; Kostadinova-Kunovska S; Krsteska B; Karagjozov P; Dzambaz D; Nikolovski A; Antovic S; Jankulovski N; Petrushevska G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2024 Jun; 45(2):47-58. PubMed ID: 39008643
    [No Abstract]   [Full Text] [Related]  

  • 13. Coexistence of MACC1 and NM23-H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early-stage colon cancer.
    Ozturk E; Aksoy SA; Ugras N; Tunca B; Ceylan S; Tezcan G; Yilmazlar T; Yerci O; Egeli U; Cecener G
    APMIS; 2018 Feb; 126(2):99-108. PubMed ID: 29700912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of tumor budding detection in stage II colon cancer].
    Liu SJ; Yang XH; Ren JQ; Zhu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):730-4. PubMed ID: 23980042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
    Trotsyuk I; Sparschuh H; Müller AJ; Neumann K; Kruschewski M; Horst D; Elezkurtaj S
    BMC Cancer; 2019 Nov; 19(1):1033. PubMed ID: 31675950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a semi-automated method for tumour budding assessment in colorectal cancer and comparison with manual methods.
    Fisher NC; Loughrey MB; Coleman HG; Gelbard MD; Bankhead P; Dunne PD
    Histopathology; 2022 Feb; 80(3):485-500. PubMed ID: 34580909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
    Kyong Shin J; Ah Park Y; Wook Huh J; Hyeon Yun S; Cheol Kim H; Yong Lee W; Hyung Kim S; Yun Ha S; Cho YB
    Dis Colon Rectum; 2023 Aug; 66(8):e801-e808. PubMed ID: 35394982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Budding Detection by Immunohistochemical Staining is Not Superior to Hematoxylin and Eosin Staining for Predicting Lymph Node Metastasis in pT1 Colorectal Cancer.
    Okamura T; Shimada Y; Nogami H; Kameyama H; Kobayashi T; Kosugi S; Wakai T; Ajioka Y
    Dis Colon Rectum; 2016 May; 59(5):396-402. PubMed ID: 27050601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.
    Zlobec I; Bächli M; Galuppini F; Berger MD; Dawson HE; Nagtegaal ID; Lugli A
    Virchows Arch; 2021 Dec; 479(6):1085-1090. PubMed ID: 33843013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial.
    Bilchik AJ; Hoon DS; Saha S; Turner RR; Wiese D; DiNome M; Koyanagi K; McCarter M; Shen P; Iddings D; Chen SL; Gonzalez M; Elashoff D; Morton DL
    Ann Surg; 2007 Oct; 246(4):568-75; discussion 575-7. PubMed ID: 17893493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.